Chicago Equity Partners’s Myriad Genetics MYGN Stock Holding History

Chicago Equity Partners’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-6,500	Closed	-$243K	–	853
2018 Q2	$243K	Buy	+6,500	New	+$220K	0.01%	770
2014 Q3	–	Sell	-202,715	Closed	-$7.89M	–	482
2014 Q2	$7.89M	Buy	202,715 +12,245	+6%	+$456K	0.21%	125
2014 Q1	$6.51M	Buy	190,470 +152,525	+402%	+$4.73M	0.18%	144
2013 Q4	$796K	Sell	37,945 -43,300	-53%	-$1.1M	0.02%	276
2013 Q3	$1.91M	Buy	81,245 +8,315	+11%	+$236K	0.06%	229
2013 Q2	$1.96M	Buy	+72,930	New	+$2.11M	0.06%	217

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Chicago Equity Partners's MYGN Position: Q3 2018 in Review

Chicago Equity Partners sold out of Myriad Genetics (MYGN) in Q3 2018, closing a stake of 6,500 shares — an estimated $243K sold.

Chicago Equity Partners first reported a position in MYGN in Q2 2013 and held it in 6 quarters. The position peaked at $7.89M in Q2 2014. 284 funds tracked by Wall St. Rank hold MYGN as of Q3 2018.

Chicago Equity Partners reported no remaining Myriad Genetics position as of Q3 2018 after selling out during the quarter.
Chicago Equity Partners sold 6,500 Myriad Genetics shares in Q3 2018, an estimated $243K.
Chicago Equity Partners first reported a position in Myriad Genetics in Q2 2013 and held it in 6 quarters.
Chicago Equity Partners's Myriad Genetics position peaked at $7.89M in Q2 2014.
284 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2018.

Based on Chicago Equity Partners's 13F filing for Q3 2018, filed 1 Nov 2018.